• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

24.43 -0.70 (-2.79%)
Delayed Quote Updated: 4:00 PM EDT, Oct 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,667,982
Open 24.88
Bid (Size) 24.40 (1,000)
Ask (Size) 24.87 (100)
Prev. Close 25.13
Today's Range 24.08 - 24.93
52wk Range 20.23 - 38.26
Shares Outstanding 79,199,501
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
October 13, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress
October 13, 2026
From Beam Therapeutics
Via GlobeNewswire

Performance

52-Week Range 36.1% below 52-week high
24.43
20.2352W Low 38.2652W High
1 Week 6.8% below 1-week high
23.911W Low 26.231W High

Beam Therapeutics Inc. - Common Stock (BEAM) traded between $20.23 and $38.26 over the past 52 weeks and last traded at $24.43, 36.1% below its 52-week high. Over the past week it ranged between $23.91 and $26.23.

Past 12 Months
-1.4%
+1.3%
-20.9%
-19.4%
-10.0%
-3.8%
1W -$0.34
1M +$0.31
3M -$6.46
6M -$5.87
YTD -$2.71
1Y -$0.96

BEAM was -3.8% over the past year, -19.4% over six months, -10.0% year to date, -1.4% in the last week.

12 Months vs Market
BEAM
-3.8%
DIA
+12.1%
SPY
+17.3%
QQQ
+23.5%
IWM
+13.2%

Over the past 12 months BEAM returned -3.8% versus DIA (Dow) +12.1%, SPY (S&P 500) +17.3%, QQQ (Nasdaq 100) +23.5% and IWM (Russell 2000) +13.2%.

Volume & Liquidity 0.89× 3-mo avg
Today 1,667,982 3-mo avg 1.9M
1W
1.9M
1M
1.9M
3M
1.9M
6M
2.1M
YTD
2.0M
1Y
2.1M

BEAM most recently traded 1,667,982 shares against a 3-month average daily volume of 1.9M.

More News

Read More
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
October 06, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
September 29, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
September 22, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
September 22, 2026
Via The Motley Fool
Topics Artificial Intelligence
News headline image
BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law
September 16, 2026
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
September 15, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
September 08, 2026
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
September 01, 2026
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
August 31, 2026
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
August 04, 2026
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
July 23, 2026
From Beam Therapeutics
Via GlobeNewswire
News headline image
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead? ↗
July 20, 2026
Via The Motley Fool
News headline image
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics ↗
July 08, 2026
Via The Motley Fool
News headline image
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration
June 18, 2026
From Beam Therapeutics
Via GlobeNewswire
News headline image
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? ↗
May 25, 2026
Via The Motley Fool
News headline image
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances ↗
May 20, 2026
Via MarketBeat
Topics Intellectual Property
News headline image
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
May 18, 2026
From Beam Therapeutics
Via GlobeNewswire
News headline image
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
May 18, 2026
Via The Motley Fool
News headline image
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
May 13, 2026
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
May 12, 2026
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
May 07, 2026
From Beam Therapeutics
Via GlobeNewswire
News headline image
3 Biotech Stocks That Could Benefit from the Patent Cliff ↗
April 27, 2026
Via MarketBeat
Topics Intellectual Property
News headline image
Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors. ↗
April 11, 2026
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Beam Therapeutics Inc. - Common Stock publicly traded?
Yes, Beam Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Beam Therapeutics Inc. - Common Stock trade on?
Beam Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Beam Therapeutics Inc. - Common Stock?
The ticker symbol for Beam Therapeutics Inc. - Common Stock is BEAM on the Nasdaq Stock Market
What is the current price of Beam Therapeutics Inc. - Common Stock?
The current price of Beam Therapeutics Inc. - Common Stock is 24.43
When was Beam Therapeutics Inc. - Common Stock last traded?
The last trade of Beam Therapeutics Inc. - Common Stock was at 10/13/26 04:00 PM ET
What is the market capitalization of Beam Therapeutics Inc. - Common Stock?
The market capitalization of Beam Therapeutics Inc. - Common Stock is 1.93B
How many shares of Beam Therapeutics Inc. - Common Stock are outstanding?
Beam Therapeutics Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap